Specializing in pharmaceutical research and development, this Japanese firm focuses on treatments for rare diseases and cardiovascular conditions. Investors monitor its pipeline of orphan drugs and international expansion efforts.
1 member of Congress has disclosed 1 trade in Nippon Shinyaku Co., Ltd. (NPPNY), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-02-27 | Daniel Goldman | sell | $1K – $15K |